These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21576339)

  • 1. Rapid immune responses to a botulinum neurotoxin Hc subunit vaccine through in vivo targeting to antigen-presenting cells.
    White DM; Pellett S; Jensen MA; Tepp WH; Johnson EA; Arnason BG
    Infect Immun; 2011 Aug; 79(8):3388-96. PubMed ID: 21576339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system.
    Yu Y; Shi D; Liu S; Gong ZW; Wang S; Sun Z
    Hum Vaccin Immunother; 2015; 11(2):468-73. PubMed ID: 25483668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and evaluation of candidate subunit vaccine against botulinum neurotoxin serotype B.
    Shi DY; Chen BY; Mao YY; Zhou G; Lu JS; Yu YZ; Zhou XW; Sun ZW
    Hum Vaccin Immunother; 2019; 15(3):755-760. PubMed ID: 30433836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Easy expression of the C-terminal heavy chain domain of botulinum neurotoxin serotype A as a vaccine candidate using a bi-cistronic baculovirus system.
    Villaflores OB; Hsei CM; Teng CY; Chen YJ; Wey JJ; Tsui PY; Shyu RH; Tung KL; Yeh JM; Chiao DJ; Wu TY
    J Virol Methods; 2013 Apr; 189(1):58-64. PubMed ID: 23313783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and evaluation of candidate subunit vaccine and novel antitoxin against botulinum neurotoxin serotype E.
    Shi DY; Liu FJ; Mao YY; Cui RT; Lu JS; Yu YZ; Dong XJ; Yang ZX; Sun ZW; Pang XB
    Hum Vaccin Immunother; 2020; 16(1):100-108. PubMed ID: 31210561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subunit vaccine efficacy against Botulinum neurotoxin subtypes.
    Henkel JS; Tepp WH; Przedpelski A; Fritz RB; Johnson EA; Barbieri JT
    Vaccine; 2011 Oct; 29(44):7688-95. PubMed ID: 21839134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological characterisation and immunoprotective efficacy of functional domain antigens of botulinum neurotoxin serotype A.
    Liu FJ; Shi DY; Mao YY; Xiong XH; Lu JS; Pang XB; Dong XJ; Yang ZX; Yu YZ
    Vaccine; 2020 Mar; 38(14):2978-2983. PubMed ID: 32113807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of a potential trivalent vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system.
    Zichel R; Mimran A; Keren A; Barnea A; Steinberger-Levy I; Marcus D; Turgeman A; Reuveny S
    Clin Vaccine Immunol; 2010 May; 17(5):784-92. PubMed ID: 20357058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel platform for engineering stable and effective vaccines against botulinum neurotoxins A, B and E.
    Liu Y; Liu X; Chen W; Yu Y; Meng J; Wang J
    Front Immunol; 2024; 15():1469919. PubMed ID: 39315101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of Hc fragment from Clostridium botulinum neurotoxin serotype B in Escherichia coli and its use as a good immunogen.
    Gao YL; Gao S; Kang L; Nie C; Wang JL
    Hum Vaccin; 2010 Jun; 6(6):462-6. PubMed ID: 20519939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pentavalent replicon vaccines against botulinum neurotoxins and tetanus toxin using DNA-based Semliki Forest virus replicon vectors.
    Yu YZ; Liu S; Ma Y; Gong ZW; Wang S; Sun ZW
    Hum Vaccin Immunother; 2014; 10(7):1874-9. PubMed ID: 25424795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Production and evaluation of a recombinant chimeric vaccine against clostridium botulinum neurotoxin types C and D.
    Gil LA; da Cunha CE; Moreira GM; Salvarani FM; Assis RA; Lobato FC; Mendonça M; Dellagostin OA; Conceição FR
    PLoS One; 2013; 8(7):e69692. PubMed ID: 23936080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection with a recombinant Hc of Clostridium Botulinum neurotoxin serotype A from Escherichia coli as an effective subunit vaccine.
    Yu YZ; Sun ZW; Li N; Wang S; Wang RL; Yu WY
    Immunopharmacol Immunotoxicol; 2009 Jun; 31(2):261-6. PubMed ID: 18932057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D.
    Moreira C; da Cunha CE; Moreira GM; Mendonça M; Salvarani FM; Moreira ÂN; Conceição FR
    Anaerobe; 2016 Aug; 40():58-62. PubMed ID: 27236078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge.
    Mustafa W; Al-Saleem FH; Nasser Z; Olson RM; Mattis JA; Simpson LL; Schnell MJ
    Vaccine; 2011 Jun; 29(28):4638-45. PubMed ID: 21549784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced potency of replicon vaccine using one vector to simultaneously co-express antigen and interleukin-4 molecular adjuvant.
    Ma Y; An HJ; Wei XQ; Xu Q; Yu YZ; Sun ZW
    Hum Vaccin Immunother; 2013 Feb; 9(2):242-9. PubMed ID: 23291932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing toxin-based vaccines against botulism.
    Przedpelski A; Tepp WH; Zuverink M; Johnson EA; Pellet S; Barbieri JT
    Vaccine; 2018 Feb; 36(6):827-832. PubMed ID: 29307477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-route targeted vaccine protects efficiently against botulinum neurotoxin A complex.
    Sahay B; Colliou N; Zadeh M; Ge Y; Gong M; Owen JL; Valletti M; Jobin C; Mohamadzadeh M
    Vaccine; 2018 Jan; 36(1):155-164. PubMed ID: 29180028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune response of horses to vaccination with the recombinant Hc domain of botulinum neurotoxin types C and D.
    Stahl C; Unger L; Mazuet C; Popoff M; Straub R; Frey J
    Vaccine; 2009 Sep; 27(41):5661-6. PubMed ID: 19646409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced effects of DNA vaccine against botulinum neurotoxin serotype A by targeting antigen to dendritic cells.
    Chen BY; Zhou G; Li QL; Lu JS; Shi DY; Pang XB; Zhou XW; Yu YZ; Huang PT
    Immunol Lett; 2017 Oct; 190():118-124. PubMed ID: 28802641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.